Browsing by Author Kim, Kevin

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)Citation
2014Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorKefford, Richard (Rick); Long, Georgina; Cebon, Jonathan Simon; et al, Various; Flaherty, Keith; Hamid, Omid; Infante, Jeffrey; Johnson, Douglas B; Kim, Kevin; McWilliams, Robert; Schuchter, Lynn; Sharfman, William; Weber, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreCombined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor, Journal of Clinical Oncology, vol.32, 33, 2014,pp 3697-3704
2012Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialKefford, Richard (Rick); Long, Georgina; Arkenau, Tobias; Brown, Michael P.; et al, various; Falchook, GErald; Hamid, Omid; Infante, Jeffrey; Kim, Kevin; Kurzrock, Razelle; Millward, Michael; O'Day, Steven; Pavlick, Anna C.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreDabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial, The Lancet, vol.379, 9829, 2012,pp 1893-1901
2014Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF-inhibitor Dabrafenib (GSK2118436)Kefford, Richard (Rick); Long, Georgina; Arkenau, Hendrik-Tobias; Brown, Michael P.; Chin, Melvin; et al, .; Falchook, Gerald; Hamid, Omid; Infante, Jeffrey; Kim, Kevin; Kurzrock, Razelle; Millward, Michael; Pavlick, Anna C.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreDose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF-inhibitor Dabrafenib (GSK2118436), Clinical Cancer Research, vol.20, 17, 2014,pp 4449-4458
2013Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic MelanomaHersey, Peter; Long, Georgina; et al, Various; Flaherty, Keith; Gonzalez, Rene; Hutson, Thomas; Kim, Kevin; McArthur, Grant A.; Moschos, Stergios; Pavlick, Anna C.; Schuchter, Lynn; Trunzer, Kerstin; Weber, Jeffrey; Northern Clinical School: Surgery; Central Clinical School: The Sydney Cancer CentrePharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.31, 14, 2013,pp 1767-1774
2013Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF InhibitorKefford, Richard (Rick); Long, Georgina; et al, Various; Fecher, Leslie A.; Gonzalez, Rene; Hwu, Patrick; Infante, Jeffrey; Kim, Kevin; McArthur, Grant A.; Millward, Michael; Pavlick, Anna C.; Ribas, Antoni; Sosman, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentrePhase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor, Journal of Clinical Oncology, vol.31, 4, 2013,pp 482-489
2013Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic MelanomaKefford, Richard (Rick); Long, Georgina; Amaravadi, Ravi; Arya, Niki; Ascierto, Paolo; et al, Various; Grob, Jean-Jacques; Guckert, Mary; Hamid, Omid; Kim, Kevin; Lebbe, Celeste; Minor, David; O'Hagan, Anne; Ribas, Antoni; Schadendorf, D; Simeone, Ester; Wilhelm, Tabea; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentrePhase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.31, 26, 2013,pp 3205-3211
2012Survival in BRAF V600-mutant advanced melanoma treated with vemurafenibHersey, Peter; Kefford, Richard (Rick); et al, Various; Flaherty, Keith; Gonzalez, Rene; Hutson, Thomas; Kim, Kevin; McArthur, Grant A.; Moschos, Stergios; Pavlick, Anna C.; Schuchter, Lynn; Sosman, Jeffrey; Weber, Jeffrey; Northern Clinical School: Surgery; Western Clinical School: Westmead Millennium InstituteSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenib, New England Journal of Medicine, vol.366, 8, 2012,pp 707-714